A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients

BACKGROUND: Cancer vaccines require adjuvants to induce effective immune responses; however, there is no consensus on optimal adjuvants. We hypothesized that toll-like receptor (TLR)3 agonist polyICLC or TLR4 agonist lipopolysaccharide (LPS), combined with CD4 T cell activation, would support strong...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Immunother Cancer
Autori principali: Melssen, Marit M., Petroni, Gina R., Chianese-Bullock, Kimberly A., Wages, Nolan A., Grosh, William W., Varhegyi, Nikole, Smolkin, Mark E., Smith, Kelly T., Galeassi, Nadejda V., Deacon, Donna H., Gaughan, Elizabeth M., Slingluff, Craig L.
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2019
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6598303/
https://ncbi.nlm.nih.gov/pubmed/31248461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0625-x
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi